Clinical Trials · NCT07743983
A Study of BGM0504 in Early T2DM With Obesity
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Enrollment
- 372
- Start date
- Aug 2026
- Locations
- 1 site, China
- Primary endpoint
- Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from Baseline